葛兰素史克以9.5亿美元收购肺动脉高压生物技术公司35Pharma。
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
生物技术与制药领域的最新动态
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
HHS commits up to $144M to study anti-aging approaches via ARPA-H
Novo Nordisk to slash Wegovy list price in half in 2027
Industry groups lay legal groundwork against pricing demos
UCLA spinout raises $11M to test microbiome-based weight loss therapy
Can the ACCESS pilot crack a longstanding barrier for startups?
BioMarin fails to find buyer, pulls Roctavian gene therapy off market
Patient dies in MacroGenics' cancer study, FDA puts trial on hold
Beam Therapeutics' new PKU program; Protara's bladder cancer data
Abcuro drug fails muscle weakness trial, development to continue
Immedica wins accelerated approval for once-rejected rare disease drug
New biotech Slate Medicines raises $130M for migraine drug from China
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Hims reports 2025 earnings, shares details on GLP-1 pill decisions
Astellas pays $240M cash for Vir's prostate cancer drug
QurAlis' ALS drug sees early positive signal, but questions remain
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act
Fortress to sell priority review voucher for $205M
FDA unveils long-awaited guidance on new pathway for individualized therapies